The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
November 8th 2024
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.
Benchmarking Health-Related Quality-of-Life Data From a Clinical Setting
Health-related quality-of-life data are often collected during routine clinical care. We present a method to create nationally representative benchmarks for clinical subspecialties.
Read More
What We're Reading: Awaiting Alzheimer's Drug Clinical Trial Results
October 13th 2016What we’re reading, October 13, 2016: researchers, Alzheimer’s patients, and their families anxiously await the results of a clinical trial that could help slow the disease’s progress; many breast cancers detected by mammograms are overtreated even though they likely would not be fatal on their own; stock prices fall for Humana and Cigna as CMS says a minority of their patients are in plans rated 4 stars or higher.
Read More
What We're Reading: Tying Medical Organization Recommendations to Insurance Coverage
October 11th 2016What we're reading, October 11, 2016: USPSTF recommendations maybe shouldn't be tied to insurance coverage; growing dispute over homeopathy research; and the harm of pharmaceutical companies' copay assistant programs.
Read More
Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC
October 10th 2016While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.
Read More
Jakafi Named Recommended Treatment for Myelofibrosis in NCCN Guideline
October 9th 2016As part of the National Comprehensive Cancer Network's new clinical guidelines for myeloproliferative neoplasms, a group of rare blood cancers, Jakafi has been recommended for the treatment of myelofibrosis.
Read More
This Week in Managed Care: October 7, 2016
October 7th 2016This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.
Watch
What We're Reading: Customers Sue UnitedHealth for Overcharging on Drugs
October 6th 2016What we're reading, October, 6, 2016: UnitedHealth is sued for allegedly overcharging on prescription drugs; the Obama administration could point consumers to remaining insurance options as insurers leave the Affordable Care Act exchanges; and human life spans may have it a ceiling.
Read More
Sustained Economic Hardship May Affect Cognitive Function at Middle Age
October 6th 2016Persistent low income in young adulthood and middle age may raise the risk for worse cognitive function by age 50, according to a study of more than 3300 adults who were followed for more than 2 decades. In addition, the study suggested that poverty and perceived hardship may be important contributors to premature aging among disadvantaged populations.
Read More
State-Level Insurance Reform Improved Access for Patients With CRC in Massachusetts
October 6th 2016A study published in the Journal of Clinical Oncology found an increased rate of resection and a reduction in the probability of emergent resection for colorectal cancer (CRC) as a result of insurance expansion in Massachusetts.
Read More
Ted Kyle Discusses BMI as a Diagnostic Tool for Obesity
October 6th 2016While body mass index is a good indicator for obesity, there are various other factors and clinical symptoms that need to be taken into account when diagnosing and treating a patient for obesity, explained Ted Kyle, RPh, MBA, principal at ConscienHealth.
Watch
Using Pharmacogenomics and Precision Medicine to Improve Treatment Options
October 5th 2016Even when following clinical guidelines, some patients will respond far better to treatment than others, and some will have worse side effects than expected. During a session at the Academy of Managed Care Pharmacy 2016 Nexus meeting, Nicole Scovis, PharmD, BCPS, BCACP, and Sandra Leal, PharmD, MPH, both of SinfoniaRx in Tucson, Arizona, explained how precision medicine can be integrated into primary care practice to improve care.
Read More
Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC
October 5th 2016A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).
Read More
PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care
October 4th 2016Precision Promise, the Pancreatic Cancer Action Network (PanCAN)'s precision medicine trial, seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020.
Read More
Specialty Pharmaceutical Pipeline: Increased Competition, Biosimilar Uncertainty
October 4th 2016Perennial favorite, Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapeutics at Express Scripts, opened the Academy of Managed Care Pharmacy 2016 Nexus, October 3, 2016, in National Harbor, Maryland, with a discussion of specialty pharmaceutical drugs in the pipeline.
Read More
Remarkable Outcomes With Cancer Immunotherapy, but Clinical Adoption Remains Challenging
October 3rd 2016The cancer community has seen tremendous progress in the field of immunotherapy. However, educating patients and care providers across healthcare on this new tool remains a significant challenge.
Read More
Dr Emma Guttman-Yassky Discusses the Role of the Immune Pathway in Atopic Dermatitis
October 1st 2016For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-driven disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
Watch
ICER Recommends Significant Discount on WAC for Checkpoint Inhibitors in NSCLC
September 30th 2016Based on ICER’s evaluation, a significant reduction in the wholesale acquisition cost (WAC) of approved checkpoint inhibitors would be necessary to achieve a pre-determined value-based price benchmark.
Read More
What We're Reading: Senate Passes Government Budget Bill With Zika Virus Funding
September 29th 2016What we're reading, September 29, 2016: as part of the bill to prevent a government shutdown, the Senate has finally approved Zika virus funding; electronic health record breaches skyrocketed from 2014 to 2015; and California passes "right to try" law for terminally ill patients.
Read More
Dr Thomas C. Quinn Outlines Measures to Prevent HIV Infection
September 29th 2016Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Watch
Preventive Oophorectomy Contraindicated in Women With an Average Risk of Ovarian Cancer
September 29th 2016Researchers at the Mayo Clinic are recommending that premenopausal women with a low risk of ovarian cancer should be spared unnecessary comorbidities associated with bilateral oophorectomy.
Read More
Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study
September 29th 2016A new study has found that after adjusting for changes in screening, there was a decrease in incidence of all grades of cervical intraepithelial neoplasia (CIN) for women 15- to 19-years old, and CIN grade 2 in women 20- to 24-years old.
Read More
Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard
September 28th 2016Mohs surgery is generally the gold standard for rare and more aggressive tumors because the surgeon can ensure the roots of the tumor are gone, but the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.
Watch